The aims of treatment in axSpA are to reduce inflammation, relieve pain and stiffness, preserve spinal mobility and prevent the development of syndesmophytes. Although there is limited evidence that non-steroidal anti-inflammatory drugs (NSAIDs) may slow the development of radiographic change [4] , standard treatment is essentially symptomatic. In contrast to peripheral arthritis, disease modifying anti-rheumatic drugs (DMARDs) have no effect on symptoms or progression of axial disease [5, 6] .
Need for updated guideline
Several major developments have occurred since the publication of the previous BSR guidelines [7] , necessitating a revision. Firstly, the 2005 guidelines applied only to the subset of patients with established AS. However, the concept of axSpA has fundamentally changed in the past decade, primarily led by improvements in imaging techniques. A growing amount of data shows that patients with nr-axSpA suffer a similar disease burden [8] and may derive as much benefit from treatment as patients with established AS. To ensure best care, treatment guidelines should apply to the whole spectrum of axSpA. Additionally, according to current National Institute for Health and Care Excellence (NICE) guidance [9] , AS patients may only switch to a second anti-TNF drug within the first 12 weeks of treatment, and then only if they suffer an adverse event. Recent published evidence now supports the sequential use of two or more anti-TNF drugs in patients who have failed to respond due to inefficacy or toxicity [10, 11] , and continuing to deny patients effective treatment is untenable.
Finally, the therapeutic arsenal has expanded over the past decade to include not just anti-TNF drugs but other biologic agents and biosimilar drugs, and these have been included in the most recent literature search.
Objectives of the guideline
These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for adult patients with axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment.
Peripheral spondyloarthritis and juvenile SpA are outside the scope of these guidelines, and readers are referred to the BSR 2012 guidelines for the management of psoriatic arthritis [12] . While a systematic approach was adopted to assess the efficacy of biologic drugs in axSpA, this did not include a health economic evaluation.
Most safety concerns with anti-TNF therapies are common to their use in all inflammatory conditions, and to avoid overlap between BSR guidelines it has been decided that the generic safety aspects will be addressed by a separate BSR guideline on the safety of biologic therapies in inflammatory arthropathies [13] (currently under revision). These guidelines therefore consider only those safety aspects of specific relevance to axSpA.
Target audience
These guidelines are intended primarily for Rheumatologists and other clinicians prescribing biologic drugs for the treatment of people with axSpA. However, they will also be of interest to specialist nurses, allied health professionals and general practitioners (GPs) involved in monitoring treatment and assessing response.
Stakeholder involvement
These guidelines have been written by a working party established by the BSR whose membership includes rheumatologists, allied health professionals, a GP, a patient representative and a representative from the National Ankylosing Spondylitis Society (NASS). Full details including conflicts of interest are listed at the end of this paper. The guidelines were presented for comment at the BSR Annual Meeting in 2015.
Rigour of Development

Scope of the literature search and strategy employed L2
The evidence for these guidelines is based on a systematic literature search of Medline The search was limited to articles in English. Outcomes of interest were efficacy in AS (including total ankylosis) and nr-axSpA,, comparing biologics, switching and withdrawing treatment, intermittent and changed dosing, predictors of response, outcome measures including radiographic outcomes, effect on extra-articular features, work productivity and absenteeism, utilisation of healthcare (all categorised as 'efficacy' in figure 1),and side effects, vaccine safety, reproductive safety and safety in patients with viral hepatitis or HIV (grouped as 'safety' in figure 1 ). The search terms and outcomes of interest were agreed by the working group in advance of the literature search.
For efficacy outcomes, only high-quality meta-analyses, systematic reviews or RCTs were considered, unless no other data was available for a particular outcome in which case observational studies with control arms were reviewed. For safety outcomes, controlled observational studies were accepted. Conference abstracts less than two years old were accepted unless the same data had been subsequently published.
Titles and abstracts were screened, and relevant full papers were each graded by two members according to the system used by the Scottish Intercollegiate Guidelines Network (SIGN)[14] (table 1) . A summary of the results of the literature search is shown in Fig. 1 .
Based on the literature review, the working party developed recommendations for treatment.
All members then anonymously stated their level of agreement with each statement on a 0-10 scale where 10 is total agreement. The resulting consensus scores are given for each recommendation below.
Statement of extent of NICE, RCP, SIGN guidelines
Since the last BSR guidelines, NICE has published guidelines for biologics in AS (TA 143 (2008) , currently being updated), and the Assessment of SpondyloArthritis international Society( ASAS) and the European League Against Rheumatism (EULAR) produced updated guidelines in 2010 which included the treatment of non-radiographic disease [15] . There have been no SIGN guidelines for the treatment of AS.
Statement of when guidelines will be updated
The literature review will be updated in 2017 to inform a revision of the guidelines in three years' time.
The guideline
An algorithm for the use of biologics in axSpA, summarising the recommendations below, is shown in figure 2 .
Eligibility criteria
These guidelines apply to adult patients with axSpA, including those meeting the modified New York criteria [1] and those with total ankylosis. The diagnosis of axSpA is beyond the scope of these guidelines. However, it should be emphasised that the ASAS classification criteria for axSpA [16] are not intended to be used as diagnostic criteria. While the European Medicines Agency (EMA) has approved the use of several anti-TNF drugs in patients with nr-axSpA, the US Food and Drug Administration (FDA) has not allowed the treatment of patients who do not fulfil the modified New York criteria, citing several concerns related to inappropriate diagnosis and treatment [17] . Clinicians should not use biologic drugs in patients who have no objective signs of inflammation, and/or whose symptoms or raised Creactive protein (CRP) might be due to conditions other than axSpA, even if they appear to fulfil the ASAS classification criteria. As always, guidelines are not a substitute for clinical judgement. Discussion with an axSpA specialist should be considered before starting treatment in a patient with nr-axSpA and no sacroiliac joint bone marrow oedema on MRI.
Assessment of disease and response to treatment
Anti-TNF drugs in AS
Eighteen eligible RCTs were identified which evaluated the efficacy of the five currently available TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab and infliximab)
in patients with AS. The main characteristics and outcomes of these trials are shown in Table 2 . These trials all had a placebo control arm apart from one study with sulfasalazine as control [18] and one which compared two doses of etanercept [19] . While the trials used a variety of definitions of "active" disease, 10 of the 16 placebo controlled studies used BASDAI (and spinal pain VAS in most) ≥4 as inclusion criteria (see Table 2 ). This definition of active disease was used in the seminal phase III AS studies for all of the TNF inhibitors, apart from etanercept [20] .
Similarly, the studies used a variety of primary efficacy end-points and time points. The inclusion criteria for eight studies also required the presence of active disease despite treatment with standard therapy (NSAIDs), due to either inadequate response or intolerance.
Ten of the 16 placebo-controlled RCTs, including all the seminal phase III studies, used the ASAS20 response rates as primary efficacy outcome, with the time scale varying between 12-24 weeks. The ASAS20 response rate defines the proportion of patients achieving an improvement of ≥20% and ≥1 unit compared with baseline in ≥3 of the following 4 domains:
patient's global assessment of disease activity, patient's assessment of pain, function (represented by the BASFI) and inflammation (represented by the mean of BASDAI questions 5 and 6 relating to morning stiffness); with no deterioration (worsening of ≥20% or 1 unit) in the remaining domain [21] . All of the placebo-controlled trials achieved the primary efficacy end-point, apart from one early study where the primary end-point (BASDAI) was assessed 8 weeks after the last infusion of infliximab [22] . The RCTs also demonstrated efficacy of the TNF inhibitors for a variety of other secondary clinical and patient reported outcomes. A meta-analysis of TNF inhibitors (no certolizumab studies were included)
reported that patients treated with anti-TNF agents were more likely to display an ASAS20 responses [24] .
While several early RCTs excluded patients with advanced or complete spinal fusion, one study specifically evaluated the efficacy of etanercept in patients with advanced radiographic spinal disease [25] . Improvement in BASDAI at 12 weeks, the primary end point, was significantly greater in the etanercept group compared with placebo. ASAS20 and ASAS40
responses were similar to those seen in trials for patients without advanced spinal disease.
The presence of vertebral or sacroiliac joint fusion should not therefore preclude the use of anti-TNF therapy.
Biosimilar drugs in AS
The PLANETAS study was the only RCT of an anti-TNF biosimilar in AS [26] . Patients with AS were randomised to receive either CT-P13 (biosimilar of infliximab; Inflectra or Remsima)
or innovator Remicade (infliximab). The regulators require biosimilars to demonstrate proof of similarity of effect, but not de novo efficacy. The comparable efficacy of CT-P13 with infliximab had already been demonstrated for RA in the PLANETRA study [27] , and is therefore not required for AS due to indication extrapolation (meaning the biosimilar license applies to all the same indications as the innovator biologic, without requiring separate RCTs for each indication). The primary outcome in the PLANETAS study was pharmacokinetic equivalence at steady state, with no statistically significant differences in the secondary clinical outcomes at week 14 or 30 (week 14 ASAS20 62.6% for CT-P13 and 70.5% for Remicade). An indirect meta-analysis reported similar efficacy of the infliximab biosimilar compared to the other TNF inhibitors [28] .
The BSR in its position statement on biosimilars [29] recommends that all patients starting on or switching to a biosimilar drug should be registered with the BSR Biologic Register 
Choice of drug
Rationale
In the absence of head-to-head comparisons, systematic reviews[48-50] have shown no statistical difference in efficacy between infliximab, golimumab, etanercept, or adalimumab in the treatment of AS (certolizumab data were not included in these comparative reviews).
There are insufficient data to comment on relative efficacy in nr-axSpA. We suggest therefore that a diagnosis of non-response should not be made before six months.
Those patients who have responded to treatment should be reviewed every six months by their rheumatology team. This allows an evaluation of drug efficacy and tolerability to be made, outcome measure data to be collected, and specific issues such as pregnancy and surgery to be discussed with patients. Most patients with axSpA will not be taking concomitant non-biologic DMARDs, so the frequency of any blood monitoring should be determined by local practice and guidelines, and the manufacturers' recommendations.
In keeping with international recommendations from the ASAS group, outcome measures should be used that capture the range of outcome domains in axSpA, including pain; physical function; spinal mobility; patient global assessment; peripheral joints and entheses; spinal stiffness; and fatigue. Depending on the timescale, it may be appropriate to use spinal x-ray as an outcome, although in clinical practice, when a decision to continue / discontinue treatment is warranted, or in short-term clinical trials, this is unnecessary.
BASDAI and spinal pain VAS have been used to assess disease activity since the publication of the last guidelines, and along with BASFI and patient global assessment form the ASAS improvement criteria commonly used as a primary outcome measure in clinical trials. While these are subjective measures, they are validated, well-understood by clinicians and patients and at the present time we see no reason to adopt other eligibility criteria for AS patients. In a small minority of patients (e.g. with cognitive or communication difficulties) it will not be possible to assess disease activity using BASDAI. In this situation, the decision to initiate and continue treatment should be made by the treating physician, taking into account the patient's overall symptoms and preferences.
As a measure of disease activity the Ankylosing Spondylitis Disease Activity Score (ASDAS)
is perhaps not as widely used as the BASDAI, although includes several of its individual questions. However, early evidence suggests that it may prove to be a more discriminatory tool in the assessment of disease activity [54] . As ASDAS is a composite index of patient reported outcomes and objectives measures of the acute-phase reaction, we would suggest that inflammatory markers are recorded -preferably CRP. These measures not only have some utility themselves, but can also contribute to the computation of the ASDAS. Machado et al [55] found that inflammation on MRI correlated better with CRP than other measures of disease activity, and concluded that the ASDAS, by including both CRP and patient-reported outcomes in its formula, better reflects spinal inflammation than other measures of disease activity.
Recommendations for assessment of response
(i) Initial efficacy response should be assessed following 3 to 6 months of therapy and responders should then be reassessed every 6 months (LOE 2+; strength of recommendation D; consensus score 8.6).
(ii) Response is defined as reduction of BASDAI and spinal pain VAS by 2 or more units from baseline (LOE 1+; strength of recommendation B; consensus score
8.3).
(iii) If, because of cognitive or communication difficulties, BASDAI cannot be used to monitor disease activity, the decision to initiate and continue therapy should be based on the treating clinician's assessment of disease activity (LOE 4; strength of recommendation D; consensus score 9).
Withdrawal of therapy
Rationale
The majority of patients will relapse within one year if treatment is withdrawn from those in remission (83% relapse with adalimumab after mean 14.7 weeks in nr-axSpA [56] ; 77% relapse with etanercept in AS [57] ). There is therefore no role for the routine withdrawal of treatment in patients who have achieved remission. Intermittent or 'on-demand' dosing of infliximab has been shown to marginally reduce costs, at the expense of poorer clinical outcomes, and cannot be recommended [58, 59] . There is no high-quality evidence to support the routine use of reduced doses of anti-TNF therapy.
The decision to withdraw treatment because of secondary non-response should not be made after a single raised BASDAI, because symptoms are subject to fluctuation. As noted above flares last 2-3 weeks on average[46] so a minimum interval of a month before reassessing is suggested. (ii) There is no evidence to support the withdrawal of anti-TNF therapy in treatment responders (LOE 2+; strength of recommendation B; consensus score 9).
Recommendations for withdrawal of therapy
Switching drugs
Rationale
At present, AS patients in the UK are only allowed access to one anti-TNF drug, unless they experience an adverse event within 12 weeks of initiating therapy (NICE TA 143). This Composite outcome measures were not available for all patients, but the number of patients meeting ASAS40 after 3 months of a second anti-TNF drug was 14/45 (31.1%) versus 76/202 (37.6%) for those who had not switched. The only significant difference between switchers (after 3 months of drug 2) and non-switchers (after 3 months of drug 1) was in the proportion achieving BASDAI 50 (28% vs 49% respectively, p=0.007). In the Czech national register ATTRA [11] , the response rates of 163 "switch" patients were compared to 1012 patients treated with a first anti-TNF drug At week 12, the mean BASDAI was 2.4 in nonswitchers and 2.6 in switchers (p=0.471). At two years, drug survival was 86% in nonswitchers, 69% in switchers on subsequent therapy and 28% in switchers on first therapy. In both studies, the numbers of patients who needed to switch because of inefficacy was extremely small and there was no difference in outcome between those switching due to adverse events or inefficacy. No studies have examined switching in nr-axSpA, but there is no reason to assume that outcomes would be significantly different in this group.
Although patients seem to do best if their first anti-TNF drug is both tolerated and effective, there is enough evidence to recommend that patients be allowed to switch to alternative anti-TNF drugs at any point during treatment, whether for reasons of inefficacy or adverse events.
Recommendation for switching drugs (i)
In the event of anti-TNF failure due to inefficacy or adverse event, an alternative anti-TNF agent should be offered if clinically appropriate (LOE 2+; strength of recommendation C; consensus score 9.7).
Safety Overall
The safety of anti-TNF therapies in axSpA is comparable to other inflammatory joint diseases such as RA. There is little evidence to suggest that safety issues differ hugely with different disease groups, and the 2010 BSR guidelines on the safety of anti-TNF therapies in RA are applicable in axSpA [13] . Pooled RCT data from Gottlieb et al for 2000 patients receiving etanercept (700 with AS) showed a serious infection risk for AS of 3.01/100 patient years compared to 3.75 for RA and 3.01 for the whole group [61] . A similar lack of difference according to indication was observed for malignancies, opportunistic infections and mortality.
Reproductive safety
While studies are limited, there is no evidence that anti-TNF therapy adversely affects sperm health in men with axial SpA [62] . For issues surrounding female reproductive safety, please see the BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids (in development).
Vaccination safety
The immune response to vaccination may be impaired in axSpA patients on anti-TNF therapies, although the data are conflicting. Two studies [63, 64] found the response to pandemic influenza vaccination to be unimpaired, one study [65] found response to pneumococcal vaccination to be impaired only if concomitant methotrexate was used, and one study [66] found response to pandemic flu vaccination was impaired by monoclonal antibody anti-TNF therapies.
It is recommended that any 'one-off' vaccinations required by the patient, such as those to prevent pneumonia, should be given before starting treatment. While receiving treatment, appropriate annual vaccinations (such as against influenza) should be given when indicated, although the responses may be attenuated. The shingles (herpes zoster) vaccine (Zostavax) contains live attenuated virus and therefore is not recommended for patients receiving anti-TNF drugs [67] .
TB
The risk of TB with anti-TNF therapies in axSpA appears similar to that seen in RA. The risk of TB was 561 per 100,000 patient years in an anti-TNF exposed Korean retrospective cohort of 354 AS patients [68] compared to 69.8 per 100,000 patient years in the general population, a similar increase in relative risk to that seen for anti-TNF treated patients with RA in the BSR biologics register (100 per 100,000 patient years for all anti-TNF therapies compared to 12 per 100,000 patient years in the general population) [69] . It appears that the risk of TB is increased in anti-TNF treated patients regardless of the indication.
It is therefore recommended that the same screening and prophylaxis for TB carried out prior to initiating anti-TNF therapy in any patient with inflammatory arthritis should be carried out for patients with axSpA, with appropriate vigilance to detect reactivation of TB on treatment should this occur. 
Uveitis
Applicability and utility
Barriers to implementation
There are two important differences between these guidelines and the current UK practice determined by NICE, namely the recommendation that treatment be extended to patients with nr-axSPA and objective evidence of inflammation, and the recommendation that sequential anti-TNF therapy be permitted. NICE guidance is currently under review, and it may be that similar changes are adopted. However, if this does not occur then it is unlikely that clinicians (at least outside Scotland) will be able to implement the BSR recommendations in full.
Mechanism for audit of the guideline
An audit proforma to assess compliance with these recommendations is available on the BSR website. It is suggested that this is applied to consecutive patients with axial SpA attending clinic, not just those prescribed anti-TNF drugs, as appropriate access to therapy is one standard to be measured.
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